UBS wuxuu ku sii haystaa Fisher & Paykel Healthcare heerka dhexe, laakiinse qiimaha ay ku saleysay kordhiyay
Published
Bangiga Swiss-ka ah ee UBS ayaa xaqiijiyay aragtidiisa ku saabsan saamiga shirkadda qalabka caafimaadka ee New Zealand ee Fisher & Paykel Healthcare. Falanqeeyayaasha waxay ku sii joogsanayaan talooyinkoodii "dhexe", taas oo macnaheedu yahay inay hadda aan ku talinayn in saamiga la iibiyo ama la iibsado.
Waqtigaas kor ayuu UBS u qaaday qiimaha loo saadaaliyay ee saamiga, kaasoo laga kordhiyay 42 ilaa 51 doollar New Zealand. Qiimaha loo saadaaliyo waa qiimaha ay falanqeeyayaasha ku filayaan saamiga mustaqbalka. Warkaasi waxaa lagu taariikhaysay 4-ta. Bisha iyo sanadka saxda ah ma jiraan macluumaadka la hayo.
Fisher & Paykel Healthcare waxay soo saartaa alaabta neefsashada daawaynta, oo ay ku jiraan maaskaro neefsasho iyo qalabka qoyaanta ah ee bukaanka qabta cudurada neefta. Shirkaddu waxay ku liistaysan tahay suuqa saamiga ee New Zealand iyo Australia. Wararkani xiisaha Jarmalka ee maalgeliyeyaasha waa mid xad-dhaaf ah, maadaama saamigu aanu ku jirin Jarmalka Index-ka Saamiga ee DAX.
UBS warkeeda kuma sheegin sababaha kor u kaca qiimaha dhanka kale. Macluumaadku waxay ku ekaan yihiin xaqiijinta talada iyo saadaasha qiimaha cusub.
Sources: MarketScreener Deutschland
More Germany news
- Mercedes-Benz Halts Investment in German Plants and Weighs Closures
- Housing Benefit Cut Dropped: 1.3 Million Households Keep Wohngeld
- Align Technology unveils new innovations for Invisalign treatment
- Large Solar Park in Merbitz Feeds Electricity into the Grid
- Nvidia shares fall sharply: How safe is pension money?
- Telekom baut Rechenzentrum für Industrie und KI aus
- Autonomous Buses to Enter Everyday Life: TUM Leads New DZM Site
- Cigarettes from the EU Abroad: Duty-Free Allowance Not Dropping for Now